⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2802553 | 0.96 | — | — | |
| SCHEMBL2802558 | 0.86 | — | — | |
| SCHEMBL2803934 | 0.84 | — | — | |
| SCHEMBL1742914 | 0.80 | — | — | |
| SCHEMBL7566969 | 0.79 | KMT2A (0.37) | — | |
| SCHEMBL2802528 | 0.73 | — | — | |
| SCHEMBL2804057 | 0.72 | — | — | |
| SCHEMBL26838502 | 0.71 | CA2 (0.33) | — | |
| SCHEMBL2807668 | 0.71 | — | — | |
| SCHEMBL15929443 | 0.70 | TLR4 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2164521-A2 | GLYCOCONJUGATES AND USE THEREOF AS VACCINE AGAINST<I>SHIGELLA FLEXNERI</I>SEROTYPE 3A AND X | Institut Pasteur (FR) | 2010-03-24 | — | — | EP | claimed |
| WO-2008155487-A2 | GLYCOCONJUGATES AND USE THEREOF AS VACCINE AGAINST SHIGELLA FLEXNERI SEROTYPE 3A AND X | INSTITUT PASTEUR (FR) | 2008-12-24 | — | — | WO | claimed |
| EP-2164521-B1 | GLYCOCONJUGATES AND USE THEREOF AS VACCINE AGAINST SHIGELLA FLEXNERI SEROTYPE 3A AND X | PASTEUR INSTITUT (FR) | 2018-09-12 | — | — | EP | disclosed |
| EP-2164521-A2 | GLYCOCONJUGATES AND USE THEREOF AS VACCINE AGAINST<I>SHIGELLA FLEXNERI</I>SEROTYPE 3A AND X | Institut Pasteur (FR) | 2010-03-24 | — | — | EP | disclosed |
| WO-2008155487-A2 | GLYCOCONJUGATES AND USE THEREOF AS VACCINE AGAINST SHIGELLA FLEXNERI SEROTYPE 3A AND X | INSTITUT PASTEUR (FR) | 2008-12-24 | — | — | WO | disclosed |